bintrafusp alfa
1 product
5 abstracts
Abstract
Final analysis of the BIMES trial, a phase II single arm study assessing efficacy and safety of bintrafusp alfa in previously treated advanced malignant pleural mesothelioma (GECP 20/09).Org: Hospital Universitario Virgen de la Victoria, Hospital Josep Trueta, Hospital Parc Taulí Sabadell, Lucus Augusti University Hospital,
Abstract
Retrospective clinical analysis of circulating tumor DNA (ctDNA)–based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response in phase 3 trial of bintrafusp alfa vs. pembrolizumab treatment of non-small cell lung cancer (NSCLC).Org: Clinical Measurements Sciences, Global Research & Development, EMD Serono Research & Development Institute, Guardant Health Inc., Clinical Biomarkers and Companion Diagnostics,
Abstract
Phase I evaluation of PRGN-2009 alone and in combination with bintrafusp alfa in patients (pts) with recurrent/metastatic (R/M) HPV-associated cancers (HPV-C).Org: Center for Immuno-Oncology, CCR, NCI, NIH, Bethesda, MD, Radiology and Imaging Services, Clinical Center, NIH, Bethesda, MD, Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, Office of Research Nursing, OCD, NCI, NIH, Bethesda, MD, Biostatistics and Data Management Section, OCD, NCI, NIH, Bethesda, MD, Precigen, Inc., Germantown, MD,
Abstract
A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies.Org: Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, NYU Langone Laura and Isaac Perlmutter Cancer Center, Genitourinary Malignancies Branch,
Abstract
Peripheral immunological response to treatment with a novel bifunctional anti-PD-L1/TGFβRII agent in recurrent/metastatic nasopharyngeal carcinoma.Org: Laboratory for Synthetic Chemistry and Chemical Biology, InnoHK, Hong Kong, China, The University of Hong Kong, Hong Kong, Department of Clinical Oncology, University of Hong Kong, Hongkong, China, Department of Clinical Oncology, The University of Hong Kong, Hong Kong, Laboratory of Synthetic Chemistry and Chemical Biology Limited, Hong Kong,
Product
M7824